{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:08:43Z","timestamp":1789776523918,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtcvsonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jtcvs.2025.07.014","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T16:50:26Z","timestamp":1752857426000},"page":"1795-1802.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neoadjuvant nonablative stereotactic body radiotherapy plus immunotherapy yields similar pathologic response as chemoimmunotherapy in non\u2013small cell lung cancer"],"prefix":"10.1016","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6204-906X","authenticated-orcid":false,"given":"Dan","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu","family":"Nasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Villena-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebron","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Shostak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Formenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Port","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9754-9945","authenticated-orcid":false,"given":"Nasser","family":"Altorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtcvs.2025.07.014_bib1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN guidelines\u00ae insights: non-small cell lung cancer, version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.jtcvs.2025.07.014_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.jtcvs.2025.07.014_bib3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jtcvs.2025.07.014_bib4","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtcvs.2025.07.014_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jtcvs.2025.07.014_bib6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtcvs.2025.07.014_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jtcvs.2025.07.014_bib8","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtcvs.2025.07.014_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jtcvs.2025.07.014_bib10","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jtcvs.2025.07.014_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.jtcvs.2025.07.014_bib12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.jtcvs.2025.07.014_bib13","article-title":"Association of pathologic complete response and long-term survival outcomes among patients treated with neoadjuvant chemotherapy or chemoradiotherapy for NSCLC: a meta-analysis","volume":"3","author":"Rosner","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"7","key":"10.1016\/j.jtcvs.2025.07.014_bib14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","article-title":"Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable NSCLC","volume":"19","author":"Hines","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jtcvs.2025.07.014_bib15","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jtcvs.2025.07.014_bib16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtcvs.2025.07.014_bib17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2020.12.045","article-title":"Radiotherapy, immunotherapy, and the tumour microenvironment: turning an immunosuppressive milieu into a therapeutic opportunity","volume":"502","author":"Donlon","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jtcvs.2025.07.014_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jtcvs.2025.07.014_bib19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/0008-5472.CAN-15-3142","article-title":"Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.jtcvs.2025.07.014_bib20","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"issue":"15","key":"10.1016\/j.jtcvs.2025.07.014_bib21","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1158\/1078-0432.CCR-06-0593","article-title":"The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas","volume":"12","author":"Newcomb","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.jtcvs.2025.07.014_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87415","article-title":"Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer","volume":"1","author":"Herter-Sprie","year":"2016","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.jtcvs.2025.07.014_bib23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.jtcvs.2025.07.014_bib24","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.jtcvs.2025.07.014_bib25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s43018-021-00245-1","article-title":"Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer","volume":"2","author":"Ban","year":"2021","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.jtcvs.2025.07.014_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jtcvs.2022.07.017","article-title":"Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: results from a randomized trial","volume":"165","author":"Lee","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.jtcvs.2025.07.014_bib27","doi-asserted-by":"crossref","first-page":"8435","DOI":"10.1038\/s41467-023-44195-x","article-title":"Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial","volume":"14","author":"Altorki","year":"2023","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jtcvs.2025.07.014_bib28","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jtcvs.2025.07.014_bib29","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtcvs.2025.07.014_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2289","article-title":"LBA48 CCTG BR.31: a global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)","volume":"35","author":"Goss","year":"2024","journal-title":"Ann Oncol"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522325005719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522325005719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:55:03Z","timestamp":1778936103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022522325005719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0022522325005719"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2025.07.014","relation":{},"ISSN":["0022-5223"],"issn-type":[{"value":"0022-5223","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant nonablative stereotactic body radiotherapy plus immunotherapy yields similar pathologic response as chemoimmunotherapy in non\u2013small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2025.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by The American Association for Thoracic Surgery","name":"copyright","label":"Copyright"}]}}